NCT04971109Phase 3Completed

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days

Study sponsor: SIGA Technologies

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-05-12Actual
Enrollment · participants467Actual
Source updated2026-09-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview